OBJECTIVE: To determine prospectively the efficacy of surfactant in acute respiratory distress syndrome. STUDY DESIGN: Twenty patients, 1 month to 16 years of age, diagnosed with an acute pulmonary disease with severe hypoxaemia (PaO2/FiO2 < 100) (13 with systemic or pulmonary disease and seven with cardiac disease) were treated with one to six doses of 50-200 mg/kg of porcine surfactant administered directly into the trachea. The surfactant was considered to be effective when the PaO2/FiO2 improved by > 20%. RESULTS: After initial surfactant administration the PaO2/FiO2 increased significantly in patients with systemic or pulmonary disease from 68 to 111, and the oxygenation index (OI) diminished significantly from 36.9 to 27.1. The PaO2/FiO2 and OI did not improve in children with cardiac disease. The improvement of the patients who survived was greater than that of those who died. CONCLUSIONS: Surfactant moderately improves oxygenation in some children with severe acute respiratory distress syndrome secondary to pulmonary or systemic disease.
OBJECTIVE: To determine prospectively the efficacy of surfactant in acute respiratory distress syndrome. STUDY DESIGN: Twenty patients, 1 month to 16 years of age, diagnosed with an acute pulmonary disease with severe hypoxaemia (PaO2/FiO2 < 100) (13 with systemic or pulmonary disease and seven with cardiac disease) were treated with one to six doses of 50-200 mg/kg of porcine surfactant administered directly into the trachea. The surfactant was considered to be effective when the PaO2/FiO2 improved by > 20%. RESULTS: After initial surfactant administration the PaO2/FiO2 increased significantly in patients with systemic or pulmonary disease from 68 to 111, and the oxygenation index (OI) diminished significantly from 36.9 to 27.1. The PaO2/FiO2 and OI did not improve in children with cardiac disease. The improvement of the patients who survived was greater than that of those who died. CONCLUSIONS: Surfactant moderately improves oxygenation in some children with severe acute respiratory distress syndrome secondary to pulmonary or systemic disease.
Authors: J López-Herce Cid; E Cueto Calvo; A Carrillo Alvarez; P Vázquez García; A Bustinza Arriortúa; R Moral Torrero Journal: An Esp Pediatr Date: 1997-06
Authors: A H Morris; C J Wallace; R L Menlove; T P Clemmer; J F Orme; L K Weaver; N C Dean; F Thomas; T D East; N L Pace; M R Suchyta; E Beck; M Bombino; D F Sittig; S Böhm; B Hoffmann; H Becks; S Butler; J Pearl; B Rasmusson Journal: Am J Respir Crit Care Med Date: 1994-02 Impact factor: 21.405
Authors: J van der Bleek; F B Plötz; F M van Overbeek; A Heikamp; H Beekhuis; R H Wildevuur; A Okken; S Bambang Oetomo Journal: Pediatr Res Date: 1993-08 Impact factor: 3.756
Authors: T J Gregory; W J Longmore; M A Moxley; J A Whitsett; C R Reed; A A Fowler; L D Hudson; R J Maunder; C Crim; T M Hyers Journal: J Clin Invest Date: 1991-12 Impact factor: 14.808
Authors: F X McGowan; M Ikegami; P J del Nido; E K Motoyama; G Kurland; P J Davis; R D Siewers Journal: J Thorac Cardiovasc Surg Date: 1993-12 Impact factor: 5.209
Authors: Andreas Schwingshackl; Benjamin Lopez; Bin Teng; Charlean Luellen; Florian Lesage; John Belperio; Riccardo Olcese; Christopher M Waters Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-24 Impact factor: 5.464
Authors: Jens Christian Möller; Thomas Schaible; Claudia Roll; Jan-Holger Schiffmann; Lutz Bindl; Lothar Schrod; Irwin Reiss; Martina Kohl; Subha Demirakca; Roland Hentschel; Thomas Paul; Anne Vierzig; Peter Groneck; Heide von Seefeld; Helmut Schumacher; Ludwig Gortner Journal: Intensive Care Med Date: 2003-02-15 Impact factor: 17.440
Authors: V Leone; A Tommasini; M Andolina; G Runti; U De Vonderweid; C Campello; L D Notarangelo; A Ventura Journal: Bone Marrow Transplant Date: 2002-07 Impact factor: 5.483